ADAPTIMMUNE THERAPEUTICS PLC's ticker is ADAP and the CUSIP is 00653A107. A total of 50 filers reported holding ADAPTIMMUNE THERAPEUTICS PLC in Q1 2017. The put-call ratio across all filers is - and the average weighting 0.1%.
Quarter-by-quarter ownership
| Value | Shares | Weighting | ||||
|---|---|---|---|---|---|---|
| Q3 2023 | $2,174,519 | -15.7% | 2,787,845 | 0.0% | 0.06% | -4.9% |
| Q2 2023 | $2,578,757 | -15.1% | 2,787,845 | 0.0% | 0.06% | -16.4% |
| Q1 2023 | $3,038,751 | -22.2% | 2,787,845 | +4.2% | 0.07% | -22.3% |
| Q4 2022 | $3,907,743 | +54.2% | 2,676,536 | +13.5% | 0.09% | +44.6% |
| Q3 2022 | $2,534,000 | -36.8% | 2,357,544 | 0.0% | 0.06% | -44.4% |
| Q2 2022 | $4,008,000 | -15.3% | 2,357,544 | +2.6% | 0.12% | -1.7% |
| Q1 2022 | $4,732,000 | -43.0% | 2,297,194 | +3.7% | 0.12% | -38.0% |
| Q4 2021 | $8,308,000 | -26.6% | 2,215,588 | +1.2% | 0.19% | -19.3% |
| Q3 2021 | $11,321,000 | +72.0% | 2,189,788 | +41.7% | 0.24% | +83.1% |
| Q2 2021 | $6,582,000 | -19.8% | 1,545,000 | 0.0% | 0.13% | -27.4% |
| Q1 2021 | $8,204,000 | -1.5% | 1,545,000 | 0.0% | 0.18% | +1.1% |
| Q4 2020 | $8,328,000 | -47.5% | 1,545,000 | -22.2% | 0.18% | -56.0% |
| Q3 2020 | $15,856,000 | -20.3% | 1,986,910 | 0.0% | 0.40% | -26.4% |
| Q2 2020 | $19,889,000 | +509.3% | 1,986,910 | +65.6% | 0.55% | +304.4% |
| Q1 2020 | $3,264,000 | +240.0% | 1,200,000 | +50.0% | 0.14% | +350.0% |
| Q4 2019 | $960,000 | -27.3% | 800,000 | -8.6% | 0.03% | -43.4% |
| Q3 2019 | $1,321,000 | -62.5% | 875,000 | 0.0% | 0.05% | -58.3% |
| Q2 2019 | $3,518,000 | +2.3% | 875,000 | +9.4% | 0.13% | -4.5% |
| Q1 2019 | $3,440,000 | -20.2% | 800,000 | +6.7% | 0.13% | -34.8% |
| Q4 2018 | $4,313,000 | -57.6% | 750,000 | 0.0% | 0.20% | -44.6% |
| Q3 2018 | $10,170,000 | +14.2% | 750,000 | 0.0% | 0.37% | +7.3% |
| Q2 2018 | $8,903,000 | -9.4% | 750,000 | -14.3% | 0.34% | -18.1% |
| Q1 2018 | $9,826,000 | +68.1% | 875,000 | 0.0% | 0.42% | +58.1% |
| Q4 2017 | $5,845,000 | -18.4% | 875,000 | 0.0% | 0.26% | -19.9% |
| Q3 2017 | $7,166,000 | +82.4% | 875,000 | 0.0% | 0.33% | +67.2% |
| Q2 2017 | $3,929,000 | -18.5% | 875,000 | 0.0% | 0.20% | -28.8% |
| Q1 2017 | $4,821,000 | +76.3% | 875,000 | +29.6% | 0.28% | +51.9% |
| Q4 2016 | $2,734,000 | -42.6% | 675,000 | 0.0% | 0.18% | -38.6% |
| Q3 2016 | $4,759,000 | -23.7% | 675,000 | -11.8% | 0.30% | -35.5% |
| Q2 2016 | $6,235,000 | +0.3% | 765,001 | 0.0% | 0.46% | -11.3% |
| Q1 2016 | $6,219,000 | -32.6% | 765,001 | 0.0% | 0.52% | -25.5% |
| Q4 2015 | $9,226,000 | +1.9% | 765,001 | +1.2% | 0.70% | -4.9% |
| Q3 2015 | $9,051,000 | -45.4% | 756,100 | -16.5% | 0.74% | -39.3% |
| Q2 2015 | $16,589,000 | – | 905,000 | – | 1.21% | – |
Download | ||||||
Other shareholders
| Name | Shares | Value | Weighting ↓ |
|---|---|---|---|
| Syncona Portfolio Ltd | 1,377,294 | $1,501,250 | 2.44% |
| NEA Management Company, LLC | 17,079,779 | $18,616,958 | 1.29% |
| Endurant Capital Management LP | 1,660,835 | $1,810,310 | 0.93% |
| Matrix Capital Management Company, LP | 38,974,185 | $42,481,862 | 0.58% |
| Long Focus Capital Management, LLC | 5,435,439 | $5,924,629 | 0.34% |
| PFM Health Sciences, LP | 5,992,571 | $6,531,902 | 0.29% |
| Key Client Fiduciary Advisors, LLC | 321,155 | $350,059 | 0.22% |
| DAFNA Capital Management LLC | 351,064 | $382,660 | 0.12% |
| Rock Springs Capital Management LP | 2,787,845 | $3,038,751 | 0.07% |
| Baker Brothers Advisors | 9,830,877 | $10,715,656 | 0.06% |